Happy Wednesday! While it's felt like January was going to last forever, we're almost through the first month of 2019. As we gear up for February, we want to reflect…
Epidermolysis Bullosa Epidermolysis Bullosa (EB) refers to a group of rare conditions which are characterized by fragile skin. Basically, the disease is caused by separation between the layers of the skin.…
According to an article from Pharmaceutical Daily, the Seattle-based drug company Sound Pharmaceuticals is set to soon begin a phase 2 clinical study for a cystic fibrosis (CF) drug candidate…
Autoimmune hepatitis (AIH) is a rare condition which causes inflammation in the liver. It can lead to cirrhosis and ultimately, liver failure. The typical treatment for patients with the disease includes…
According to a story from BioPortfolio, the biotechnology company Vertex Pharmaceuticals recently announced that the European Commission has approved a label extension for the company's cystic fibrosis drug Orkambi. Under…
UPI Health News recently reported that a study, published in the New England Journal of Medicine, showed that fecal microbiota transplantation resulted in a 32 percent remission rate in patients…
A January 4th post by the Lancet's EBioMedicine headlined the first-in-human pilot study results published by UT Health San Antonio in collaboration with the Mayo Clinic and the Wake Forest School…
According to a story from Medical Xpress, a collaborative team of scientists from UT Health San Antonio, the Mayo Clinic, and the Wake Forest School of Medicine, have recently released…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
